ArQule Announces First Patient Dosed in Registrational MOSIAC Trial of Miransertib for the Treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum
ARQULE (ARQL)
Last arqule earnings: 10/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.arqule.com/investor-relations
Company Research
Source: Business Wire
MOSAIC trial represents the first registrational trial for Proteus Syndrome and PIK3CA-related overgrowth spectrum BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL), today announced that the first patient was dosed in the registrational MOSAIC (Miransertib in Overgrowth Syndromes in Adults and Children) trial of its oral, selective pan-AKT inhibitor, miransertib, for the treatment of Proteus syndrome (PS) and PIK3CA-related Overgrowth Spectrum disorders (PROS). The MOSAIC trial represents the first registrational trial of its kind for patients suffering from these rare genetic conditions characterized by mutations in the PI3K/AKT pathway that emerge in childhood and early adolescence.“After years of extensive preclinical and clinical efforts among ArQule and our collaborators, the MOSAIC trial represents an important milestone for patients with Proteus syndrome and PROS, their families and caregivers,” said Brian Schwartz, Chief Medical Officer of ArQule. “These pati
Show less
Read more
Impact Snapshot
Event Time:
ARQL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQL alerts
High impacting ARQULE news events
Weekly update
A roundup of the hottest topics